Centiva Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Centiva Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,672	Closed	-$20K	–	1592
2022 Q3	$20K	Buy	+1,672	New	+$22.6K	﹤0.01%	1385

Other funds holding RIGL

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's RIGL Position: Q4 2022 in Review

Centiva Capital sold out of Rigel Pharmaceuticals (RIGL) in Q4 2022, closing a stake of 1,672 shares — an estimated $20K sold.

Centiva Capital first reported a position in RIGL in Q3 2022 and held it in 1 quarter. The position peaked at $20K in Q3 2022. 119 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.

Centiva Capital reported no remaining Rigel Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Centiva Capital sold 1,672 Rigel Pharmaceuticals shares in Q4 2022, an estimated $20K.
Centiva Capital first reported a position in Rigel Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Centiva Capital's Rigel Pharmaceuticals position peaked at $20K in Q3 2022.
119 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.

Based on Centiva Capital's 13F filing for Q4 2022, filed 14 Feb 2023.